Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.51 |
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | HTR2B | P41595 | 6/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5136312 | 0.94 | HTR2A (0.44) | HTR2AHTR2CHTR2BCTSLPOLB | |
| SCHEMBL5135658 | 0.94 | HTR2A (0.52) | HTR2AHTR2CHTR2BCTSLPOLB | |
| SCHEMBL5137845 | 0.93 | HTR2A (0.54) | HTR2AHTR2CHTR2BCTSLPOLB | |
| SCHEMBL5134864 | 0.91 | HTR2A (0.57) | HTR2AHTR2CHTR2BTP53SMN1; SMN2 | |
| SCHEMBL5137540 | 0.90 | HTR2A (0.53) | HTR2AHTR2CHTR2BPOLBTP53 | |
| SCHEMBL5137390 | 0.88 | C5AR1 (0.44) | HTR2AHTR2CHTR2BPOLBC5AR1 | |
| SCHEMBL4768999 | 0.88 | C5AR1 (0.51) | HTR2AHTR2CHTR2BCTSLPOLB | |
| SCHEMBL5136966 | 0.88 | HTR2A (0.43) | HTR2AHTR2CHTR2BCTSLPOLB | |
| SCHEMBL5136963 | 0.87 | C5AR1 (0.47) | HTR2AHTR2CHTR2BPOLBC5AR1 | |
| SCHEMBL5138029 | 0.87 | C5AR1 (0.53) | HTR2AHTR2CHTR2BCTSLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |